WO1994012184A1 - Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis - Google Patents
Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis Download PDFInfo
- Publication number
- WO1994012184A1 WO1994012184A1 PCT/US1992/009932 US9209932W WO9412184A1 WO 1994012184 A1 WO1994012184 A1 WO 1994012184A1 US 9209932 W US9209932 W US 9209932W WO 9412184 A1 WO9412184 A1 WO 9412184A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- mycophenolate mofetil
- mycophenolic acid
- acceptable salt
- derivative
- Prior art date
Links
- 0 CC1OC(*)(*)OC1 Chemical compound CC1OC(*)(*)OC1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31782/93A AU3178293A (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
PCT/US1992/009932 WO1994012184A1 (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
JP6513067A JPH08503487A (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or their derivatives to control stenosis |
CA002144189A CA2144189A1 (en) | 1992-11-24 | 1992-11-24 | Prevention of stenosis |
EP93900534A EP0670724A1 (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
KR1019950702066A KR950703966A (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or derivate according to inhibit stenosis |
NO951966A NO951966L (en) | 1992-11-24 | 1995-05-18 | |
FI952479A FI952479A0 (en) | 1992-11-24 | 1995-05-22 | Prevention of stenosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1992/009932 WO1994012184A1 (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
CA002144189A CA2144189A1 (en) | 1992-11-24 | 1992-11-24 | Prevention of stenosis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994012184A1 true WO1994012184A1 (en) | 1994-06-09 |
Family
ID=25677830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/009932 WO1994012184A1 (en) | 1992-11-24 | 1992-11-24 | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1994012184A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0746314A1 (en) * | 1992-07-10 | 1996-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US5932600A (en) * | 1997-03-14 | 1999-08-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US6107052A (en) * | 1999-06-09 | 2000-08-22 | Roche Diagnostics Corporation | Enzymatic measurement of mycophenolic acid |
US6128582A (en) * | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
US6399773B1 (en) | 1998-10-29 | 2002-06-04 | Bristol-Myers Squibb Co. | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
US6420403B1 (en) | 1998-10-29 | 2002-07-16 | Edwin J. Iwanowicz | Inhibitors of IMPDH enzyme |
US6514979B1 (en) | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
US6518291B1 (en) | 1997-03-14 | 2003-02-11 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US6541496B1 (en) | 1996-04-23 | 2003-04-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
WO2003032978A1 (en) * | 2001-10-17 | 2003-04-24 | Novartis Ag | Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
US6596747B2 (en) | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
US6624184B1 (en) | 1998-10-29 | 2003-09-23 | Bristol-Myers Squibb Company | Amide and diamide inhibitors of IMPDH enzyme for use in treating IMPDH-associated disorders |
EP1349562A2 (en) * | 2001-01-11 | 2003-10-08 | Duke University | Inhibiting gs-fdh to modulate no bioactivity |
EP1441224A2 (en) | 2003-01-14 | 2004-07-28 | Roche Diagnostics GmbH | Enzyme inhibition immunoassay |
US6916809B2 (en) | 2001-12-21 | 2005-07-12 | Bristol-Myers Squibb Company | Heterocyclic acridone inhibitors of IMPDH enzyme |
US6919335B2 (en) | 2000-04-24 | 2005-07-19 | Bristol-Myers Squibb Co. | Heterocycles that are inhibitors of IMPDH enzyme |
EP1559779A1 (en) | 2004-01-30 | 2005-08-03 | Boehringer Mannheim Gmbh | Modified inosine monophosphate dehydrogenases |
WO2007093346A1 (en) * | 2006-02-13 | 2007-08-23 | Novartis Ag | High dosage of mycophenolic acid (mpa) |
EP1964561A1 (en) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US7777069B2 (en) | 1999-06-25 | 2010-08-17 | Vertex Pharmaceuticals Incorporated | Prodrugs of carbamate inhibitors of IMPDH |
WO2013041205A1 (en) * | 2011-09-19 | 2013-03-28 | Pyxirion Pharma Gmbh | Novel therapeutic concepts for treating vascular diseases |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US8957071B2 (en) | 2005-02-08 | 2015-02-17 | Aspreva Pharmaceuticals S.A. | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686234A (en) * | 1985-11-27 | 1987-08-11 | Syntex (U.S.A) Inc. | Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis |
US4725622A (en) * | 1986-01-23 | 1988-02-16 | Syntex (U.S.A.) Inc. | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis |
US4727069A (en) * | 1987-01-30 | 1988-02-23 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions |
EP0281713A1 (en) * | 1987-01-30 | 1988-09-14 | Syntex (U.S.A.) Inc. | Morpholinoethylester of mycophenolic acid and derivatives thereof, their preparation and use in pharmaceutical compositions |
-
1992
- 1992-11-24 WO PCT/US1992/009932 patent/WO1994012184A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686234A (en) * | 1985-11-27 | 1987-08-11 | Syntex (U.S.A) Inc. | Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis |
US4725622A (en) * | 1986-01-23 | 1988-02-16 | Syntex (U.S.A.) Inc. | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis |
US4727069A (en) * | 1987-01-30 | 1988-02-23 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions |
EP0281713A1 (en) * | 1987-01-30 | 1988-09-14 | Syntex (U.S.A.) Inc. | Morpholinoethylester of mycophenolic acid and derivatives thereof, their preparation and use in pharmaceutical compositions |
Non-Patent Citations (4)
Title |
---|
FASEB vol. J6, no. 4, April 1992, page A940 C. GREGORY ET AL. 'USE OF ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF OCCLUSIVE VASCULAR DISEASE' * |
SURGICAL FORUM vol. 43, October 1992, pages 383 - 385 D.M. STEELE ET AL. 'RS-61443 INHIBITS INTIMAL HYPERPLASIA IN AORTIC ALLOGRAFTS' * |
'THE MERCK MANUAL' 1987 , MERCK SHARP & DOHME RESEARCH LABORATORIES , RAHWAY, N.J. CORONARY ARTERIAL BYPASS SURGERY AND ANGIOPLASTY * |
TRANSPLANTATION PROCEEDINGS vol. 25, no. 1, 1993, pages 770 - 771 C.R. GREGORY ET AL. 'EFFECTS OF TREATMENT WITH CYCLOSPORINE, FK 506, RAPAMYCIN, MYCOPHENOLIC ACID, OR DEOXYSPERGUALIN ON VASCULAR MUSCLE PROLIFERATION IN VITRO AND IN VIVO' * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0746314A4 (en) * | 1992-07-10 | 1997-03-19 | Univ Leland Stanford Junior | Method of treating hyperproliferative vascular disease |
EP0746314A1 (en) * | 1992-07-10 | 1996-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
US7329681B2 (en) | 1996-04-23 | 2008-02-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6541496B1 (en) | 1996-04-23 | 2003-04-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US6967214B2 (en) | 1996-04-23 | 2005-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6344465B1 (en) | 1996-04-23 | 2002-02-05 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US7216041B1 (en) | 1996-04-30 | 2007-05-08 | Vertex Pharmaceuticals Incorporated | Methods of using the structure coordinates of molecules comprising an IMPDH-like binding pocket |
US6128582A (en) * | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
US7527952B2 (en) | 1996-04-30 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Crystals of inosine monophosphate dehydrogenase/oxidized inosine monophosphate thiomidate intermediate/mycophenolic acid (IIMPDH/XMP*/MPA) |
US6518291B1 (en) | 1997-03-14 | 2003-02-11 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5932600A (en) * | 1997-03-14 | 1999-08-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6624184B1 (en) | 1998-10-29 | 2003-09-23 | Bristol-Myers Squibb Company | Amide and diamide inhibitors of IMPDH enzyme for use in treating IMPDH-associated disorders |
US6596747B2 (en) | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
US6617323B2 (en) | 1998-10-29 | 2003-09-09 | Bristol-Myers Squibb Co. | Amino-substituted compounds useful as inhibitors of IMPDH enzyme |
US6399773B1 (en) | 1998-10-29 | 2002-06-04 | Bristol-Myers Squibb Co. | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
US6420403B1 (en) | 1998-10-29 | 2002-07-16 | Edwin J. Iwanowicz | Inhibitors of IMPDH enzyme |
US7205324B2 (en) | 1998-10-29 | 2007-04-17 | Bristol-Myers Squibb Company | Inhibitors of IMPDH enzyme |
US7060720B2 (en) | 1998-10-29 | 2006-06-13 | Bristol-Myers Squibb Co. | Inhibitors of IMPDH enzyme |
US7053111B2 (en) | 1998-10-29 | 2006-05-30 | Bristol-Myers Squibb Co. | Inhibitors of IMPDH enzyme |
US6514979B1 (en) | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
US8268873B2 (en) | 1999-03-19 | 2012-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
EP1964561A1 (en) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6107052A (en) * | 1999-06-09 | 2000-08-22 | Roche Diagnostics Corporation | Enzymatic measurement of mycophenolic acid |
US7777069B2 (en) | 1999-06-25 | 2010-08-17 | Vertex Pharmaceuticals Incorporated | Prodrugs of carbamate inhibitors of IMPDH |
US6919335B2 (en) | 2000-04-24 | 2005-07-19 | Bristol-Myers Squibb Co. | Heterocycles that are inhibitors of IMPDH enzyme |
EP1349562A2 (en) * | 2001-01-11 | 2003-10-08 | Duke University | Inhibiting gs-fdh to modulate no bioactivity |
US8217006B2 (en) | 2001-01-11 | 2012-07-10 | Duke University | Inhibiting GS-FDH to modulate no bioactivity |
EP1349562A4 (en) * | 2001-01-11 | 2008-08-06 | Univ Duke | Inhibiting gs-fdh to modulate no bioactivity |
US7615535B2 (en) | 2001-01-11 | 2009-11-10 | Duke University | Inhibiting GS-FDH to modulate no bioactivity |
WO2003032978A1 (en) * | 2001-10-17 | 2003-04-24 | Novartis Ag | Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
US6916809B2 (en) | 2001-12-21 | 2005-07-12 | Bristol-Myers Squibb Company | Heterocyclic acridone inhibitors of IMPDH enzyme |
EP1441224A2 (en) | 2003-01-14 | 2004-07-28 | Roche Diagnostics GmbH | Enzyme inhibition immunoassay |
EP1559779A1 (en) | 2004-01-30 | 2005-08-03 | Boehringer Mannheim Gmbh | Modified inosine monophosphate dehydrogenases |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US8957071B2 (en) | 2005-02-08 | 2015-02-17 | Aspreva Pharmaceuticals S.A. | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors |
WO2007093346A1 (en) * | 2006-02-13 | 2007-08-23 | Novartis Ag | High dosage of mycophenolic acid (mpa) |
WO2013041205A1 (en) * | 2011-09-19 | 2013-03-28 | Pyxirion Pharma Gmbh | Novel therapeutic concepts for treating vascular diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994012184A1 (en) | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis | |
US5922757A (en) | Treatment and prevention of hepatic disorders | |
Heyman et al. | Myoglobinuric acute renal failure in the rat: a role for medullary hypoperfusion, hypoxia, and tubular obstruction. | |
EP0646005B1 (en) | Use of an imidazole for the preparation of a medicament for the treatment of arteriosclerosis | |
KR20010015807A (en) | Use of 9-deoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease | |
KR940000008B1 (en) | Pharmaceutical composition for treating hyperlipidemia | |
KR20190077131A (en) | Pharmaceutical combination comprising a selective s1p1 receptor agonist | |
JP3194964B2 (en) | Organ or tissue protectant | |
CA2568436A1 (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
EP0612733B1 (en) | Use of 5-amino-Phthaloylhydrazide as Anti-Hypoxic and defensive Agent | |
US6348493B1 (en) | Treatment and prevention of hepatic disorders | |
EP0670724A1 (en) | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis | |
JPH06234636A (en) | Use of leflunomide for inhibiting interleukin-8 | |
US5789439A (en) | Pharmaceutical use of forskolin derivatives | |
US5977121A (en) | Use of moxonidine for the treatment of atherosclerosis | |
US7495024B2 (en) | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque | |
JPH07196509A (en) | Pharmaceutical composition containing isoquinoline derivative | |
EA003671B1 (en) | Riluzole and alpha-tocopherol combination | |
JPS5896021A (en) | Remedy for oxygen poisoning | |
US5232950A (en) | Method for using ketamine for prevention or reduction of the effects of stroke in a subject having increased risk for stroke | |
JP3533491B2 (en) | Angiogenesis inhibitor | |
HUT72753A (en) | Pharmaceutical compositions containing mycophenolic acid derivatives for inhibiting stenosis | |
CA2144189A1 (en) | Prevention of stenosis | |
WO1999004783A1 (en) | Composition for protection from damage by ischemia | |
EP0952830A1 (en) | Use of raloxifene and of related compounds for the manufacture of a medicament for lowering plasma levels of lipoprotein(a) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2144189 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993900534 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 952479 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1993900534 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993900534 Country of ref document: EP |